Joint Supplement Contains Undeclared Allergens
Xymogen and the FDA are notifying health professionals and consumers of the recall of Atriphen because it contains the undeclared allergens, soy and milk. Atriphen is a dietary supplement currently marketed for the support of healthy joint function.
Xymogen immediately discontinued sale of Atriphen upon learning that it might contain the two allergens. A third-party laboratory test was conducted to confirm the presence of allergens. Consumers who have an allergy or severe sensitivity to either milk or soy are at risk of serious or life-threatening allergic reactions if they take this product.
Consumers are urged to return this product for a full refund.